Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meisoindigo SCHEMBL13299737 | 1.00 | TTR (0.50) | TTRCES1MAPTMEN1KMT2A | |
| Meisoindigo SCHEMBL24186711 | 1.00 | TTR (0.50) | TTRCES1MAPTMEN1KMT2A | |
| Meisoindigo SCHEMBL29361307 | 1.00 | TTR (0.50) | TTRCES1MAPTMEN1KMT2A | |
| Meisoindigo SCHEMBL31053331 | 0.98 | TTR (0.49) | TTRCES1MAPTMEN1KMT2A | |
| SCHEMBL30639320 | 0.85 | NR1H2 (0.53) | TTRCES1MAPTMEN1KMT2A | |
| SCHEMBL30639330 | 0.85 | CES1 (0.47) | TTRCES1MAPTMEN1KMT2A | |
| SCHEMBL29141585 | 0.85 | NR1H2 (0.53) | TTRCES1MAPTMEN1KMT2A | |
| SCHEMBL31053327 | 0.85 | NR1H2 (0.56) | TTRCES1MEN1KMT2AEPHX2 | |
| SCHEMBL31053337 | 0.85 | EGFR (0.42) | TTRCES1MEN1KMT2ALRRK2 | |
| SCHEMBL30639332 | 0.85 | PIM1 (0.46) | TTRCES1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440073-B1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| EP-3865481-A1 | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO[4,5-D]AZEPINE DERIVATIVES AS JANUS KINASE INHIBITORS | Topivert Pharma Limited (GB) | 2021-08-18 | — | — | EP | disclosed |
| EP-3831830-A1 | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO[4,5-D]AZEPINE DERIVATIVES AS JANUS KINASE INHIBITORS | Topivert Pharma Limited (GB) | 2021-06-09 | — | — | EP | disclosed |
| US-10941115-B2 | Kinase inhibitors | OXULAR ACQUISITIONS LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| EP-3712152-B1 | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO[4,5-D]AZEPINE DERIVATIVES AS JANUS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-10882859-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2021-01-05 | — | — | US | disclosed |
| US-10851097-B2 | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2020-12-01 | — | — | US | disclosed |
| EP-3371185-B1 | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO[4,5-D]AZEPINE DERIVATIVES AS JANUS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-09-30 | — | — | EP | disclosed |
| EP-3712152-A1 | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO[4,5-D]AZEPINE DERIVATIVES AS JANUS KINASE INHIBITORS | Topivert Pharma Limited (GB) | 2020-09-23 | — | — | EP | disclosed |
| US-20200223843-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2020-07-16 | — | — | US | disclosed |
| US-20120058121-A1 | METHODS AND COMPOSITIONS FOR TREATING LUPUS | NATROGEN THERAPEUTICS INTERNATIONAL, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110160157-A1 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE | NATROGEN THERAPEUTICS INTERNATIONAL, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7855223-B2 | Method of treating inflammatory arthritis | NATROGEN THERAPEUTICS INTERNATIONAL, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-1458734-B1 | DERIVATIVES OF ISOINDIGO, INDIGO AND INDIRUBIN AND USE IN TREATING CANCER | NATROGEN THERAPEUTICS INC (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100137356-A1 | AZAINDOLE-INDOLE COUPLED DERIVATIVES, PREPARATION METHODS AND USES THEREOF | Cheng, Jingcai (CN) | 2010-06-03 | — | — | US | disclosed |
| US-20100137356-A1 | AZAINDOLE-INDOLE COUPLED DERIVATIVES, PREPARATION METHODS AND USES THEREOF | Cheng, Jingcai (CN) | 2010-06-03 | — | — | US | disclosed |
| US-20100098702-A1 | METHOD OF TREATING ANDROGEN INDEPENDENT PROSTATE CANCER | NATROGEN THERAPEUTICS INTERNATIONAL, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090325895-A1 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE | NATROGEN THERAPEUTICS INTERNATIONAL, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7582670-B2 | methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof | NATROGEN THERAPEUTICS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070027203-A1 | Method of treating inflammatory arthritis | NATROGEN THERAPEUTICS INTERNATIONAL, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851097-B2 | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors | JAK1, JAK3, JAK2 | TTR 3741/4885CES1 1384/4885MAPT 4742/4885 |
| US-20070027203-A1 | Method of treating inflammatory arthritis | IDO1, IPO7, IDO2 | TTR 248/4885CES1 1721/4885MAPT 890/4885 |
| US-20120058121-A1 | METHODS AND COMPOSITIONS FOR TREATING LUPUS | CCNO, IKZF3, CDK7 | TTR 1529/4885CES1 3400/4885MAPT 2745/4885 |
| US-20100137356-A1 | AZAINDOLE-INDOLE COUPLED DERIVATIVES, PREPARATION METHODS AND USES THEREOF | IDO1, IDO2, INMT | TTR 4334/4885CES1 2072/4885MAPT 3762/4885 |
| US-20100098702-A1 | METHOD OF TREATING ANDROGEN INDEPENDENT PROSTATE CANCER | KLK3, CYP17A1, HSD17B7 | TTR 4675/4885CES1 992/4885MAPT 4299/4885 |
| US-10941115-B2 | Kinase inhibitors | SYK, LYN, BTK | TTR 4419/4885CES1 1444/4885MAPT 3648/4885 |
| US-20090325895-A1 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE | TNF, IL36G, IL17A | TTR 405/4885CES1 1694/4885MAPT 509/4885 |
| US-10882859-B2 | Kinase inhibitors | JAK1, JAK3, JAK2 | TTR 4300/4885CES1 1488/4885MAPT 4084/4885 |
| US-20200223843-A1 | KINASE INHIBITORS | JAK1, JAK3, JAK2 | TTR 4300/4885CES1 1488/4885MAPT 4084/4885 |
| US-20110160157-A1 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE | CDK7, TNF, CDK8 | TTR 1385/4885CES1 2398/4885MAPT 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.